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Abstract
Background: Granulocyte colony stimulating factor (G-CSF) regulates survival, proliferation, and differentiation of
neutrophilic granulocyte precursors, Recombinant G-CSF has been used for the treatment of congenital and
therapy-induced neutropenia and stem cell mobilization. Due to its intrinsic instability, recombinant G-CSF needs to
be excessively and/or frequently administered to patients in order to maintain a plasma concentration high
enough to achieve therapeutic effects. Therefore, there is a need for the development of G-CSF derivatives that are
more stable and active in vivo.
Methods: Using site-direct mutagenesis and recombinant DNA technology, a structurally modified derivative of
human G-CSF termed G-CSFa was obtained. G-CSFa contains alanine 17 (instead of cysteine 17 as in wild-type G-
CSF) as well as four additional amino acids including methionine, arginine, glycine, and serine at the amino-
terminus. Purified recombinant G-CSFa was tested for its in vitro activity using cell-based assays and in vivo activity
using both murine and primate animal models.
Results: In vitro studies demonstrated that G-CSFa, expressed in and purified from E. coli, induced a much higher
proliferation rate than that of wild-type G-CSF at the same concentrations. In vivo studies showed that G-CSFa
significantly increased the number of peripheral blood leukocytes in cesium-137 irradiated mice or monkeys with
neutropenia after administration of clyclophosphamide. In addition, G-CSFa increased neutrophil counts to a higher
level in monkeys with a concomitant slower declining rate than that of G-CSF, indicating a longer half-life of G-
CSFa. Bone marrow smear analysis also confirmed that G-CSFa was more potent than G-CSF in the induction of
granulopoiesis in bone marrows of myelo-suppressed monkeys.
Conclusion: G-CSFa, a structurally modified form of G-CSF, is more potent in stimulating proliferation and
differentiation of myeloid cells of the granulocytic lineage than the wild-type counterpart both in vitro and in vivo.
G-CSFa can be explored for the development of a new generation of recombinant therapeutic drug for leukopenia.
Background
Granulocyte colony stimulating factor (G-CSF) is the
principal cytokine that regulates survival, proliferation,
and differentiation of neutrophilic granulocyte precur-
sors [1-3], and it functionally activates mature blood
neutrophils as well [4-7]. Among the family of colony-
stimulating factors, G-CSF is the predominant inducer
of terminal differentiation of granulocytes [8]. Recombi-
nant human G-CSF has been used as a therapeutic drug
for leukopenia of cancer patients who receive myelo-
suppressive radio-or chemotherapy [9,10]. In recent
years, recombinant G-CSF has also been used for the
treatment of congenital neutropenia and stem cell mobi-
lization [11,12]. It has been more than fifteen years since
recombinant G-CSF was successfully used in the clinics.
Due to its intrinsic instability, G-CSF needs to be exces-
sively and/or frequently administered to patients in
order to maintain a plasma concentration high enough
to achieve therapeutic effects. This administration regi-
men not only causes inconvenience and pains in
patients but also increases the chance for infections.
Therefore, there is a necessity for the development of
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vivo. Here, we report that G-CSFa, a recombinant G-
CSF derivative, exhibits potent biological activities both
in vivo and in vitro and that these activities appear to
result from an enhanced stability of modified G-CSF
and its binding affinity to the cognate receptor.
Methods
Animals
Male BALB/CICR C57 mice with an average weight of
22.5 ± 1.2 g (20.0 ~ 24.9 g), and monkeys with an average
weight of (5.4 ± 1.0 kg) were selected for our studies.
Animals were housed in individual stainless steel cages in
a study room with a regulated temperature of 24 ± 2°C,
relative humidity of 50 ± 10%, and a 12-h light cycle. All
animal experiments were conducted in compliance with
the Guidelines for Animal Experimentation issued by the
Chinese Association for Laboratory Animal Science and
the Standards Relating to the Care and Management of
Experimental Animals throughout the study.
Mutant G-CSF and Expression of G-CSFa in E. Coli
G-CSF cDNA was obtained through reverse transcrip-
tase-mediated polymerase chain reaction (RT-PCR)
using total RNAs isolated from human monocytes. The
primers used for PCR were as follows: upstream primer,
5’ TGG ATC CAT GAC CCC CCT GGG CCC 3’ and
downstream primer, 5’ TAA GAT CTC AAG CTT
TCA GGG CTG CGC AAG GTG GCG TA3’.T h e
amplified products were fractionated on agarose gels.
The G-CSF cDNA eluted from the agarose gel was
digested by Bam HI and Hind III, and ligated to plasmid
pQE3 that had been cut with the same restriction
enzymes. The ligation mixture was transformed into
Escherichia coli JM109 competent cells for characteriza-
tion of the cloned cDNA. Mutant G-CSF (G-CSF
C17A)
was made by replacing codon TGC with codon GCC
through site-direct mutagenesis. The identity of G-CSF
cDNA, as well as the introduced mutation, was con-
firmed by a thorough DNA sequencing analysis. The
pQE3 plasmid expressing mutant G-CSF (G-CSFa) was
transformed into E. coli M15 cells for expression.
Expression of G-CSFa was induced by isopropylthio-b-
d-galactoside (IPTG).
Refolding and purification of G-CSFa
E. Coli pellets were disrupted with addition of lysozyme
(5 mg/liter culture) in 0.1 M TrisHCl buffer (pH 8.0).
Inclusion body was collected by washing three times
with an extraction buffer [50 mM TrisHCl (pH 8.0), 2
mM EDTA, 2 M urea] and it was dissolved in a buffer
containing a high concentration of urea [50 mM
TrisHCl (pH 8.0), 2 mM EDTA, 8 M urea, 2% DTT].
Refolding of recombinant G-CSFa was achieved by
dialysis against 50 mM TrisHCl buffer (pH 8.0) for
three times (12 h intervals). Refolded recombinant G-
CSFa was purified by anion exchange chromatography
and size exclusion chromatography. Recombinant G-
CSFa was stored in 50 mM acetic acid-sodium acetate
buffer (pH 5.4) containing 5% mannitol. Purified protein
was also subjected to protein sequencing analysis using
the Edman degradation method [13].
Western blotting
Protein samples fractionated on denaturing (SDS) polya-
crylamide gels (4% stacking gel, 12% separating gel)
were transferred to a polyvinylidene difluoride (PVDF)
membrane. The membrane was blocked in a 2% bovine
serum albumin (BSA) solution for 1 hr and then incu-
bated for 1 hr with a monoclonal antibody to G-CSF (R
& D systems). After washing three times with a TrisHCl
buffer, the membrane was incubated for 1 hr with a
goat-anti-mouse immunoglobulin G (IgG) conjugated
with alkaline phosphatase. Specific signals on the mem-
brane were visualized by addition of substrate, O-pheny-
lene diamine (OPD).
In vitro bioactivity assay
In vitro activity of recombinant G-CSFa was determined
using the murine myelobalstic cell line NFS-60 as ori-
ginally described by Shirafuji [14]. We also employed
this bioassay method as described above for measuring
the activity of human G-CSF using NFS-60 cells.
Recombinant G-CSF made in house as well as commer-
cial one were used as positive controls.
Animal neutropenia models
BALB/CICR C57 male mice with an average weight of
22.5 ± 1.2 g were irradiated with cesium-137 (4 Gy)
using Gammacell-40 apparatus (Nurolion, Canada) to
induce leukopenia. To induce leukopenia in Monkeys,
animals were intravenously administered with cyclopho-
sphamide at a dose of 50 mg/kg/day for 2 days.
Measurement of mice bone marrow DNA content
Mouse femur was cleaned and washed with 5 mM
CaCl2. Bone marrow cells were flushed out with a 10 ml
5 mM CaCl2 solution. Bone marrow cells were placed at
4°C for 30 min and then centrifuged (2,500 RPM × 15
min). The pellet was resuspended in 5 ml 0.2 M HClO,
heated at 90°C for 15 min, and filtrated through a 0.45
μm filter after cooling. DNA content was determined by
measuring the absorbance of the solution at 260 nm
(A260nm) in a spectrophotometer.
Cytology
Monkey bone marrow was aspirated from the posterior
iliac crest. Bone marrow slides were prepared in a
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jected to routine Wright’s staining. Peripheral white
blood cells and neutrophils were counted using an auto-
mated hematology cell counter (Biochem
Immunosystem).
Statistical analysis
Data obtained from mouse studies were subjected to
statistical analysis using aQt e s t .D a t ao b t a i n e df r o m
monkey studies were subjected to statistical analysis
using a Newman-Keuls test. The results were considered
statistically significant when P value was less than 0.05.
Results
Structurally modified G-CSF (G-CSFa) was expressed in
E. coli using a pQE vector expression system. Following
the addition of IPTG, recombinant G-CSFa was highly
induced (Figure 1). In fact, G-CSFa was the most predo-
minant protein in the bacterial cell lysates after induc-
tion. Recombinant G-CSFa was subjected to extensive
purification using a combination of biochemical
approaches. SDS-PAGE analysis revealed that recombi-
nant G-CSFa was purified to homogeneity and remained
intact (Figure 1A). Immunoblotting analysis showed that
the G-CSF antibody detected IPTG-induced G-CSFa in
the total bacterial lysates as well as its the purified form
(Figure 2), suggesting that the amino acid addition and
substitution do not significantly change the overall con-
formation of protein. Protein sequencing analysis
confirmed that the purified protein was the modified
form of G-CSF with the addition of methionine, argi-
nine, glycine, and serine residues at the amino-terminus
and with cysteine-17 replaced by alanine as predicted
(Figure 1B).
To determine the in vitro activity of purified G-CSFa,
we employed a cell proliferation assay using NFS-60
cells as described [14]. We observed that the addition of
G-CSFa greatly stimulated the proliferation rate of NFS-
60 cells (Figure 3). G-CSFa was more potent in
Figure 1 Analysis of expression and purification of
recombinant G-CSFa. (A) G-CSFa was expressed and purified as
described in Materials and Methods. Purified G-CSFa (lane 3) and
bacterial cell lysates before (lane 1) and after (lane 2) IPTG addition
were analyzed by SDS-PAGE. Lane M stands for molecular markers.
Each experiment was repeated for at least three times and
representative data are shown. (B) N-terminal amino acid sequences
of G-CSFa determined by Edman degradation method. The mutated
amino acid residues are highlighted in red.
Figure 2 Immunoblot analysis of purified recombinant G-CSFa.
Purified G-CSFa was blotted with the antibody to G-CSF (lane 3).
Lane 1, negative control (bacterial cell lysates without IPTG
induction). Lane 2, bacterial cell lysates with IPTG induction. Each
experiment was repeated for at least three times and representative
data are shown.
Figure 3 A comparison of in vitro activity between G-CSFa and
wild-type G-CSF. Recombinant G-CSFa and G-CSF at indicated
concentrations (10 pg, 20 pg, 100 pg, 200 pg, 1 μg, and 20 μg per
milliliter, respectively) were used for the stimulation of NFS-60 cell
proliferation. The concentrations that stimulate 50% cell proliferation
rate (ED50) were obtained for each cytokine. Each experiment was
repeated for at least three times and similar results were obtained.
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wild-type recombinant G-CSF at the same concentra-
tions (Figure 3). In fact, ED50 for G-CSFa was about
10-fold lower than that for wild-type G-CSF.
We next determined the in vivo activity of G-CSFa
using the murine model. Irradiated mice were injected
with wild-type G-CSF or with G-CSFa for 5 days as
described in Materials and Methods. Peripheral white
blood cell counts were determined at various times after
cytokine injection. We observed that peripheral leuke-
cytes in mice decreased drastically after irradiation and
gradually increased to about 2/3 of the original level
during the course of three weeks. Similar to that of G-
CSF, G-CSFa was effective in stimulating the recovery of
white blood cells in the irradiated mice (Figure 4; Table
1). At 50 μg/ml concentration, G-CSFa, but not G-CSF,
was able to sustain an elevated white blood cell counts
at day 26 and beyond. At day 34, which was six days
after the cessation of cytokine administration, the white
blood cell counts in peripheral blood of mice injected
with G-CSFa remained at 128% (100 μg/ml) and 113%
(50 μg/ml) of the level before irradiation, respectively.
On the other hand, wild-type G-CSF was unable to sup-
port the full recovery of white blood cells to the pre-
irradiation level by day 26 and beyond (Figure 4; Table
1). Bone marrow cellularity was determined by measur-
ing the total DNA content. After irradiation for 8 days,
the total DNA content of the marrow cells from mice
injected with G-CSFa or G-CSF was significantly higher
than that injected with vehicle although there was no
significant difference in the DNA content between mice
injected with G-CSF or G-CSFa (Table 2).
We next test the in vivo efficacy of G-CSFa in stimu-
lating neutrophil production using the primate model.
Anemic monkeys were obtained by the injection with
cyclophosphamide (CTX) for 2 days at a dose of 50 mg/
kg/day. Five days after CTX injection, G-CSFa was
administered daily via s.c. for successive 13 days. Wild-
type of G-CSF at the same dose was administered into
separate groups of monkeys as a positive control. Abso-
lute neutrophil counts (ANC) in peripheral blood were
determined at various times post cytokine treatment.
ANC in control monkeys treated with the vehicle
remained low for almost three weeks before bouncing
back to the pretreatment level (Figure 5). In contrast,
b o t hG - C S Fa n dG - C S F aw e r ea b l et or e d u c eb o t ht h e
degree and the duration of neutropenia, which were
characterized by a dual-peak curve of neutrophil
increase. The first peak appeared at day 7 and the sec-
ond peak between day 12 and day 17. At day 7, G-CSFa,
b u tn o tG - C S F ,i n d u c e das i g n i f i c a n t( 3 7 % )i n c r e a s ei n
neutrophils compared with the pretreatment level
(Figure 5). Consistent with the mouse data, the effect of
G-CSFa on neutrophil production lasted longer than
that of G-CSF. After the cessation of cytokine adminis-
tration at day 22, ANC in monkeys administered with
G-CSFa (10 ug/kd/day), but not G-CSF (10 μg/kg/day),
remained significantly above the pretreatment level with
CTX.
We next directly examined neutrophil production in
bone marrow of monkeys undergone various treatments.
Microscopic examination revealed that the level of
nucleated cells in monkeys administrated with vehicle
alone was very low, consistent with the neutropenic
condition induced by CTX (Figure 6). However, treat-
ment with G-CSF resulted in a significant increase in
the number of nucleated cells, most of which belong to
the neutrophil lineage. Consistent with the ANC kinetics
shown above, G-CSFa also stimulated the production of
nucleated cells in bone marrow and the stimulation was
more potent than G-CSF at the same dosage. Morpholo-
gical analysis indicated that these cells were primarily
neutrophils of various differentiation stages.
Discussion
G-CSF is a glycoprotein with a molecular mass of
approximate 20 kDa. It is a bioactive molecule that has
been extensively used in the clinic as a therapeutic
agent for supporting the production of blood cells of the
neutrophil linage [15]. It also displays biological effects
on various aspects of hematopoiesis both in vivo and in
vitro [8]. G-CSF has widely used in the clinic for over
15 years, primarily for accelerating neutrophil recovery
Figure 4 Neutrophil recovery in irradiated mice administered
with G-CSFa and wild-type G-CSF. Groups of mice (n = 12)
irradiated with cesium-137 for five days were administered daily
with G-CSFa or G-CSF at the indicated doses. Mean white blood cell
(WBC) counts were obtained at day 5, day 9, day 12, day 16, day 19,
day 23, day 26, and day 34 after irradiation. The data were
summarized from two independent experiments.
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d5 d9 d12 d16 d19 d23 d26 d34
Control 11413 ± 2089 1233 ± 553 2450 ± 1104 2533 ± 850 3342 ± 811 5083 ± 260 7925 ± 1667 7575 ± 1858 8750 ± 2203
Wt G-CSF (50 mg/kg) 10996 ± 2731 1342 ± 337 3100 ± 1408 2667 ± 502 6358 ± 1398 9858 ± 2333
a 14650 ± 2861
b 11092 ± 2319
a 10592 ± 1547
G-CSFa (25 mg/kg) 11083 ± 2724 855 ± 342 2508 ± 923 1900 ± 972 5483 ± 973 8192 ± 2721 11192 ± 4593
a 12917 ± 2921
b 10533 ± 1741
G-CSFa (50 mg/kg) 10178 ± 4014 1100 ± 412 2042 ± 687 2508 ± 565 5325 ± 1139 9250 ± 3766
a 10975 ± 3052
a 13950 ± 3087
b 13075 ± 3120
a
G-CSFa (100 mg/kg) 11814 ± 3802 1175 ± 344 2783 ± 1233 4483 ± 1394 6325 ± 1726 13467 ± 4719
b 15650 ± 3572
b 15700 ± 4278
b 13383 ± 2696






























































































8in cancer patients with myelo-suppressive chemotherapy
or radiotherapy [9,10]. G-CSF is a glycoprotein although
glycosylation is not essential for its bioactivity. Clinical
studies have demonstrated that recombinant non-glyco-
sylated G-CSF expressed in and purified from E. coli
displays almost the same therapeutic efficacy as glycosy-
lated form of G-CSF [11,16]. Native G-CSF contains five
cysteine residues. They form two internal disulfide
bonds (Cys36-Cys42 and Cys64-Cys74), leaving one
cysteine residue (Cys17) with a free sulfhydryl group. It
is conceivable that this free cysteine residue may pose
some problems during G-CSF purification and refolding.
Firstly, the presence of Cys17 may increase the fre-
quency of mismatch during the formation of intra-
molecular disulfide bonds, resulting in a reduced yield
of refolding. Secondly, it is possible that the free sulfhy-
dryl group in cysterine residues may interfere with the
stability of G-CSF. In other words, Cys17 may form
inter-molecular disulfide bonds, resulting in the forma-
tion of G-CSF oligomers under certain oxidized condi-
tion. Oligomerization can conceivably lead to a decrease
in the availability of G-CSF.
We reason that the substitu t i o no fc y s t e i n e1 7w i t h
alanine may result in an enhanced bioavailability and
bioactivity of G-CSF, possibly through the elimination of
oligomerization caused by the formation of inter-mole-
cular disulfide bonds. In fact, our cell-based assays and
in vivo studies in both mice and monkeys are consistent
with the notion. Significantly, as evidenced from the
examination of the first peak of neutrophil increase (Fig-
ure 5), G-CSFa induced a much higher level of ANC
than G-CSF did. Although it is relative small this
increase is of great value for patients receiving myelo-
suppressive therapies. It is the period when patients are
most susceptible to infections due to drastic neutrophil
reduction. Therefore, a shortened window in which
patients have low neutrophil counts will greatly facilitate
them to combat deleterious infections. Further support-
ing this notion, a separate pharmacokinetic study reveals
that G-CSFa exhibits both better stability in vitro and
higher bioavailability in vivo than wild-type G-CSF [17].
G-CSF exerts its activity through the interaction with
its receptor (G-CSF-R). Upon binding to G-CSF-R, G-
CSF induces a signal transduction cascade in target
cells, leading to various biological manifestations
including cell proliferation and differentiation. G-CSF
Figure 6 Bone marrow cellularity of mice treated with G-CSFa
or wild-type G-CSF. Bone marrow cells from mice treated with G-
CSFa or G-CSF were subjected to routine Wright staining and
examined under a light microscope. Representative cell images at
low magnification (10 ×) and high magnification (40 ×) are shown.
Table 2 DNA content of mouse bone marrow cells
Groups OD260 nm
Vehicle 0.65 + 0.12
Wt G-CSF (50 μg/kg) 1.01 + 0.34*
G-CSFa (25 μg/kg) 0.95 + 0.13*
G-CSFa (50 μg/kg) 1.01 + 0.14*
G-CSFa (100 μg/kg) 1.02 + 0.20*
Irradiated (4 Gy) mice were administered daily via s.c. with cytokine or vehicle
as indicated. Left femur was obtained for bone marrow cell collection. These
cells were subsequently processed for analysis of total DNA contents. *: p <
0.01 vs. vehicle
Figure 5 Neutrophil recovery in neutropenia monkeys
administered with G-CSFa and wild-type G-CSF. Neutropenia
monkeys were obtained by injection with CTX for 2 days as
described in Materials and Methods. Five days after CTX injection,
groups of monkey (n = 5) were administered daily via s.c. for 13
days. Peripheral blood absolute neutrophil counts (ANC) were
determined at day 5, day 7, day 8, day 10, day 12, day 15, day 17,
day 20, day 22, and day 24. The data were summarized from two
independent experiments and similar results were obtained.
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anti-parallel 4-helix bundles and long overhand loops.
The major binding site on G-CSF has been shown to
include residues in A and C helices [18,19]. Further
studies indicates that Glu19 in the A helix of G-CSF
molecule electrostatically inter-reacts with Arg288 of
G-CSF-R [20,21]. A recent study on the crystal struc-
ture of G-CSF, complexed with the cytokine homolo-
gous region of G-CSF-R, reveals that residues in the
amino-terminus of G-CSF may act as additional con-
tact sites with G-CSF-R, which is unstructured in the
unbound protein [22]. In this respect, the addition of
arginine, glycine, and serine residues in the amino-ter-
m i n u so fG - C S F at h a tr e s u l t si nam o r ep o s i t i v ec h a r g e
in the amino-terminus of G-CSFa may further enhance
the binding between the cytokine and its receptor.
This may also contribute to the higher bioactivity
observed with the mutant G-CSF. It is conceivable that
the tighter binding to its cognate receptor may render
G-CSFa to be dissociated from its receptor at a slower
rate, resulting in a longer time of action both in vivo
and in vitro. In fact, G-CSF with a single amino acid
substitution (Cys17 to Ala17) shows a better stability
in plasma [17]. Therefore, we believe that the same
mutation in G-CSFa also contributes to the enhanced
bioactivities.
During the past decade or so, great efforts have been
directed to finding a more stable and thus more effec-
tive G-CSF because of its instability in vivo. PEGylated
G-CSF has been reported to enhance the stability of this
cytokine. However, the steric hindrance effect of PEGy-
lated proteins significantly suppresses the specific bind-
ing of PEGylated proteins to their cognate receptors or
substrates [23]. Besides, pegylation calls for an additional
modification step after obtaining purified target protein,
which makes the production process inconvenient and
adds costs to the production. In the current study, we
report that G-CSFa exhibits an enhanced bioactivity due
likely to its better stability. As a chronic toxicity study
shows that G-CSFa does not exhibit significant toxicity
and immunogenicity in rats [24], this cytokine derivative
can be further explored for the development of a new
generation of therapeutic agents for patients with
neutropenia.
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